The Influence of Hepatic and Renal Impairment on the Pharmacokinetics of a Treatment for Herpes Zoster, Amenamevir (ASP2151): Phase 1, Open-Label, Single-Dose, Parallel-Group Studies

Introduction Amenamevir (ASP2151) is a nonnucleoside human herpesvirus helicase-primase inhibitor that was approved in Japan for the treatment of herpes zoster (shingles) in 2017. This article reports the results of two clinical trials that investigated the effects of renal and hepatic impairment on...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Advances in therapy 2017-12, Vol.34 (12), p.2612-2624
Hauptverfasser:	Kusawake, Tomohiro, Kowalski, Donna, Takada, Akitsugu, Kato, Kota, Katashima, Masataka, Keirns, James J., Lewand, Michaelene, Lasseter, Kenneth C., Marbury, Thomas C., Preston, Richard A.
Format:	Artikel
Sprache:	eng
Schlagworte:	Cardiology Endocrinology Health technology assessment Internal Medicine Medicine Medicine & Public Health Oncology Original Research Pharmacology/Toxicology Rheumatology
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!